Enzo Biochem (ENZ) 10-Q 8 Jun 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Apr. 30, 2017	Jun. 01, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		46,407,331
Amendment Flag	false
Entity Central Index Key	316,253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Current assets:
Cash and cash equivalents	$ 62,627	$ 67,777
Accounts receivable, net of allowances	15,805	14,592
Inventories	7,170	6,971
Prepaid expenses and other	1,860	2,057
Total current assets	87,462	91,397
Property, plant and equipment, net	8,093	8,214
Goodwill	7,452	7,452
Intangible assets, net	3,244	4,422
Other assets	326	336
Total assets	106,577	111,821
Current liabilities:
Accounts payable – trade	9,400	9,857
Accrued liabilities	6,761	8,211
Loan payable		1,557
Other current liabilities	797	943
Total current liabilities	16,958	20,568
Other liabilities	1,057	1,699
Total liabilities	18,015	22,267
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,407,331 at April 30, 2017 and 46,267,619 at July 31, 2016	464	463
Additional paid-in capital	327,771	326,288
Accumulated deficit	(241,994)	(239,396)
Accumulated other comprehensive income	2,321	2,199
Total stockholders’ equity	88,562	89,554
Total liabilities and stockholders’ equity	$ 106,577	$ 111,821

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Apr. 30, 2017	Jul. 31, 2016
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	46,407,331	46,267,619
Common Stock, shares outstanding	46,407,331	46,267,619

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Revenues:
Clinical laboratory services	$ 19,584	$ 18,162	$ 56,979	$ 52,775
Product revenues	7,312	8,001	21,721	22,266
Royalty and license fee income	193	270	933	1,129
Total revenues	27,089	26,433	79,633	76,170
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services	11,334	11,142	33,282	32,009
Cost of product revenues	3,582	3,846	10,411	10,663
Research and development	766	882	2,071	2,610
Selling, general and administrative	10,502	10,869	33,141	32,374
Provision for uncollectible accounts receivable	620	576	1,968	1,739
Legal fee expense	512	1,632	1,254	5,644
Legal settlements, net				(18,450)
Total operating costs, expenses and legal settlements, net	27,316	28,947	82,127	66,589
Operating income (loss)	(227)	(2,514)	(2,494)	9,581
Other income (expense):
Interest	115	(40)	240	(122)
Other	(74)	22	69	87
Foreign exchange gain (loss)	147	419	(308)	(99)
Income (loss) before income taxes	(39)	(2,113)	(2,493)	9,447
Provision for income taxes	(32)	(2)	(105)	(296)
Net income (loss)	$ (71)	$ (2,115)	$ (2,598)	$ 9,151
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0	$ (0.05)	$ (0.06)	$ 0.20
Diluted (in Dollars per share)	$ 0	$ (0.05)	$ (0.06)	$ 0.20
Weighted average common shares outstanding:
Basic (in Shares)	46,367	46,201	46,310	46,115
Diluted (in Shares)	46,367	46,201	46,310	46,450

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Net income (loss)	$ (71)	$ (2,115)	$ (2,598)	$ 9,151
Other comprehensive income (loss):
Foreign currency translation adjustments	(116)	(222)	122	66
Comprehensive income (loss)	$ (187)	$ (2,337)	$ (2,476)	$ 9,217

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Apr. 30, 2017 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2016	$ 463	$ 326,288	$ (239,396)	$ 2,199	$ 89,554
Balance, Shares (in Shares) at Jul. 31, 2016	46,267,619
Net loss for the period ended April 30, 2017			(2,598)		(2,598)
Vesting of restricted stock, Shares (in Shares)	2,813
Exercise of stock options		159			$ 159
Exercise of stock options, Shares (in Shares)	45,358				45,358
Share-based compensation charges		601			$ 601
Issuance of common stock for 401(k) plan match	$ 1	723			$ 724
Issuance of common stock for 401(k) plan match, Shares (in Shares)	91,541				91,541
Foreign currency translation adjustments				122	$ 122
Balance at Apr. 30, 2017	$ 464	$ 327,771	$ (241,994)	$ 2,321	$ 88,562
Balance, Shares (in Shares) at Apr. 30, 2017	46,407,331

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ (2,598)	$ 9,151
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization of property, plant and equipment	1,552	1,602
Amortization of intangible assets	1,140	1,260
Provision for uncollectible accounts receivable	1,968	1,739
Deferred income tax benefit		(8)
Share-based compensation charges	601	370
Accrual for share-based 401(k) employer match expense	552	560
Foreign exchange loss	267	14
Changes in operating assets and liabilities:
Accounts receivable	(3,192)	(3,040)
Other receivables		6,650
Inventories	(213)	447
Prepaid expenses and other	195	402
Accounts payable – trade	(459)	396
Accrued liabilities, other current liabilities and other liabilities	(1,707)	(1,970)
Total adjustments	704	7,853
Net cash (used in) provided by operating activities	(1,894)	17,004
Cash flows from investing activities:
Capital expenditures	(1,424)	(1,389)
Security deposits and other	6	(1)
Net cash used in investing activities	(1,418)	(1,390)
Cash flows from financing activities:
Proceeds from borrowings under Credit Agreement	40,694	67,343
Repayments under Credit Agreement	(42,250)	(68,356)
Installment loan and capital lease obligation payments	(428)	(424)
Proceeds from the exercise of stock options	159	66
Net cash used in financing activities	(1,825)	(1,371)
Effect of exchange rate changes on cash and cash equivalents	(13)	8
(Decrease) increase in cash and cash equivalents	(5,150)	14,251
Cash and cash equivalents - beginning of period	67,777	18,109
Cash and cash equivalents - end of period	$ 62,627	$ 32,360

Basis of Presentation

Basis of Presentation	9 Months Ended
	Apr. 30, 2017
Disclosure Text Block [Abstract]
Basis of Accounting [Text Block]	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The consolidated balance sheet as of April 30, 2017, the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended April 30, 2017 and 2016, and the consolidated statements of stockholders’ equity and cash flows for the nine months ended April 30, 2017 and 2016 are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated interim financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2016 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2016 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2017 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2017. Effect of New Accounting Pronouncements Recently Adopted Accounting Pronouncements In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). We adopted this standard for the fiscal year ending July 31, 2017. The adoption of this update did not have any impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment Pronouncements Issued but Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In May 2017, the FASB issued ASU 2017-09 , “ Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Net income (loss) per share

Net income (loss) per share	9 Months Ended
	Apr. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. As a result of the net loss for the three and nine months ended April 30, 2017 and three months ended April 30, 2016 diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options and unvested restricted stock because to do so would be antidilutive. For the three and nine months ended April 30, 2017 and the three months ended April 30, 2016, the number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted earnings per share was 987,000, 865,000 and 444,000, respectively. For the nine months ended April 30, 2016, approximately 337,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. For the three and nine months ended April 30, 2017, the effect of zero and 165,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and nine months ended April 30, 2016, the effect of approximately 235,000 and 282,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	9 Months Ended
	Apr. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows For the nine months ended April 30, 2017 and 2016, income taxes paid by the Company were $1,021 and $207, respectively . For the nine months ended April 30, 2017 and 2016, interest paid by the Company was $99 and $112. For the nine months ended April 30, 2017 and 2016, the Company financed $69 and $76 respectively, in machinery and transportation equipment under installment loans. During the nine months ended April 30, 2017, the Company did not enter into any capital lease agreements. During the nine months ended April 30, 2016, the Company entered into $1,186 in capital lease agreements. During the nine months ended April 30, 2017 and 2016, the Company issued shares of common stock in connection with its share-based 401(k) employer match in the amount of $724 and $709, respectively.

Inventories

Inventories	9 Months Ended
	Apr. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories Inventories consist of the following: April 30, July 31, Raw materials $ 939 $ 951 Work in process 1,881 1,755 Finished products 4,350 4,265 $ 7,170 $ 6,971

Goodwill and intangible assets

Goodwill and intangible assets	9 Months Ended
	Apr. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 5 – Goodwill and intangible assets At April 30, 2017 and July 31, 2016, the Company’s net carrying amount of goodwill, related to the Clinical Labs segment, is $7,452. The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (1,140 ) (1,140 ) Foreign currency translation (159 ) 121 (38 ) April 30, 2017 $ 27,491 $ (24,247 ) $ 3,244 Intangible assets, all finite lived, consist of the following: April 30, 2017 July 31, 2016 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,931 ) $ 96 $ 11,027 $ (10,905 ) $ 122 Customer relationships 12,034 (8,948 ) 3,086 12,122 (8,331 ) 3,791 Website and acquired content 1,006 (1,006 ) — 1,011 (1,011 ) — Licensed technology and other 481 (450 ) 31 485 (437 ) 48 Trademarks 2,943 (2,912 ) 31 3,005 (2,544 ) 461 Total $ 27,491 $ (24,247 ) $ 3,244 $ 27,650 $ (23,228 ) $ 4,422 At April 30, 2017, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 3.5 years Trademarks 5 years 0.5 year Other intangibles 10 years 2.5 years At April 30, 2017, the weighted average useful life of intangible assets is approximately three years.

Loan Payable

Loan Payable	9 Months Ended
	Apr. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 6 - Loan Payable In June 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and MidCap Financial LLC. (formerly Healthcare Finance Group, LLC). The nominal interest rate for the four month period the loan was outstanding during fiscal year 2017 and year ended July 31, 2016 was 5.25%. The effective interest rate for the credit agreement was 14.3% for the four month period the loan was outstanding in fiscal 2017 and 11.4% for the fiscal year ended July 31, 2016. The Credit Agreement expired and was repaid in full on December 7, 2016.

Accrued Liabilities and Other C

Accrued Liabilities and Other Current Liabilities	9 Months Ended
	Apr. 30, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 – Accrued Liabilities and Other Current Liabilities Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 3,956 $ 3,956 Professional fees 526 503 Legal fee expense 458 954 Research and development — 300 Other 1,821 2,498 $ 6,761 $ 8,211

Other Liabilities

Other Liabilities	9 Months Ended
	Apr. 30, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 8 – Other Liabilities Other liabilities consist of the following: April 30, July 31, Capital lease obligations, net of short term $ 618 $ 794 Accrued legal settlement 400 800 Installment loans, net of short term 39 105 $ 1,057 $ 1,699 As of April 30, 2017, future minimum payments under the capital leases, net of interest of $140 aggregates $861 including a short term debt portion of $243 included in other current liabilities. Future minimum payments under the installment loans aggregate $186, including a short term portion of $147 included in other current liabilities. A total of $400 is included in other current liabilities and $400 in other liabilities as accrued legal settlement which is further discussed in Note 12 - Contingencies.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Apr. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity Controlled Equity Offering In March 2013, the Company entered into a Controlled Equity Offering SM In December 2014, the Sales Agreement was amended in order for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering price of $20.0 million. In connection with the amendment to the Sales Agreement, the Company also filed with the Security and Exchange Commission (“SEC”) a prospectus supplement dated December 31, 2014. Most recently with respect to the Sales Agreement, the Company filed a “shelf” registration and prospectus supplement dated September 1, 2016 which was declared effective by the SEC on November 3, 2016. During the nine months ended April 30, 2017 and 2016, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation The Company has an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 10 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2016. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2017 2016 2017 2016 Stock options $ 204 $ 143 $ 586 $ 351 Restricted stock 5 6 15 19 $ 209 $ 149 $ 601 $ 370 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2017 2016 2017 2016 Cost of clinical laboratory services $ 2 $ 2 $ 5 $ 5 Selling, general and administrative 207 147 596 365 $ 209 $ 149 $ 601 $ 370 No excess tax benefits were recognized during the nine month periods ended April 30, 2017 and 2016. Stock Option Plans The following table summarizes stock option activity during the nine month period ended April 30, 2017: Options Weighted Weighted Aggregate Outstanding at July 31, 2016 1,808,875 $ 3.43 Awarded 493,996 $ 7.07 Exercised (45,358 ) $ 3.28 $ 338 Cancelled or expired (9,000 ) $ 4.74 Outstanding at end of period 2,248,513 $ 4.23 2.7 years $ 10,433 Exercisable at end of period 1,484,993 $ 3.26 1.2 years $ 8,231 As of April 30, 2017, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is twenty months. The intrinsic value of in the money stock option awards that are vested at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options vested. Restricted Stock Awards A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2017 is as follows: Awards Weighted Outstanding at July 31, 2016 8,501 $ 4.13 Awarded — — Vested (2,813 ) $ (3.49 ) Forfeited — — Unvested at end of period 5,688 $ 1.96 The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2017, there was approximately $0.01 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately seven months. The fair value of the awards that vested during the nine months ended April 30, 2017 and 2016 was $19 and $30, respectively. The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 333,000 shares as of April 30, 2017. During the nine months ended April 30, 2017, the Company contributed $724 to match its employees’ 401(k) contributions by issuing 91,541 shares of its common stock, representing the fair value of the shares at the date of issuance, and adjusted common stock and additional paid in capital by the same amount. During the nine months ended April 30, 2016, the Company contributed $709 to match its employees’ 401(k) contributions by issuing 160,352 shares of its common stock, representing the fair value of the shares at the date of issuance, and adjusted common stock and additional paid in capital by the same amount.

Income taxes

Income taxes	9 Months Ended
	Apr. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income taxes At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods. The Company’s effective tax rate provision for the three months ended April 30, 2017 and 2016 was 82.0% and de minimis, respectfully. The Company’s effective tax rate provision for the nine months ended April 30, 2017 and 2016 was 4.2% and 3.1%, respectively. The tax provision for the 2017 periods was based on state, local and foreign taxes. The tax provision for the nine months ended April 30, 2016 included a provision for federal alternative minimum tax. The Company’s effective tax rate for all periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit. The Company files a consolidated Federal income tax return. The Company files combined returns in various states and New York City. Certain subsidiaries file separate state and foreign tax returns.

Segment reporting

Segment reporting	9 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 11 – Segment reporting The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property and other general corporate matters is considered a component of the Other segment. Legal fee expense specific to other segments’ activities has been allocated to those segments. Legal settlements, net represent activities for which royalties would have been received by the Company’s Life Sciences segment had the Company had agreements in place with plaintiffs for the patents or products covered by the settlements. Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended July 31, 2016. The following financial information represents the operating results of the reportable segments of the Company: Three months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 19,584 — — — $ 19,584 Product revenues — $ 7,312 — — 7,312 Royalty and license fee income — 193 — — 193 19,584 7,505 — — 27,089 Operating costs and expenses: Cost of clinical laboratory services 11,334 — — — 11,334 Cost of product revenues — 3,582 — — 3,582 Research and development — 552 $ 214 — 766 Selling, general and administrative 6,118 2,745 — $ 1,639 10,502 Provision for uncollectible accounts receivable 650 (30 ) — — 620 Legal fee expense 4 42 — 466 512 Total operating costs and expenses 18,106 6,891 214 2,105 27,316 Operating income (loss) 1,478 614 (214 ) (2,105 ) (227 ) Other income (expense): Interest (28 ) 12 — 131 115 Other 7 (98 ) — 17 (74 ) Foreign exchange loss — 147 — — 147 Income (loss) before income taxes $ 1,457 $ 675 $ (214 ) $ (1,957 ) $ (39 ) Depreciation and amortization included above $ 390 $ 423 $ — $ 37 $ 850 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 38 $ 23 — $ 146 207 Total $ 40 $ 23 $ — $ 146 $ 209 Capital expenditures $ 483 $ 252 $ — $ — $ 735 Three months ended April 30, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,162 — — — $ 18,162 Product revenues — $ 8,001 — — 8,001 Royalty and license fee income — 270 — — 270 18,162 8,271 — — 26,433 Operating costs and expenses: Cost of clinical laboratory services 11,142 — — — 11,142 Cost of product revenues — 3,846 — — 3,846 Research and development — 674 $ 208 — 882 Selling, general and administrative 6,008 2,877 — $ 1,984 10,869 Provision for uncollectible accounts receivable 612 (36 ) — — 576 Legal fee expense 54 11 — 1,567 1,632 Legal settlements, net — — — — — Total operating costs and expenses 17,816 7,372 208 3,551 28,947 Operating income (loss) 346 899 (208 ) (3,551 ) (2,514 ) Other income (expense) Interest (33 ) 7 — (14 ) (40 ) Other 2 4 — 16 22 Foreign exchange loss — 419 — — 419 Income (loss) before income taxes $ 315 $ 1,329 $ (208 ) $ (3,549 ) $ (2,113 ) Depreciation and amortization included above $ 418 $ 514 $ — $ 28 $ 960 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 14 $ 9 — $ 124 147 Total $ 16 $ 9 $ — $ 124 $ 149 Capital expenditures $ 331 $ 115 $ — $ — $ 446 Nine months ended April 30, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 56,979 — — — $ 56,979 Product revenues — $ 21,721 — — 21,721 Royalty and license fee income — 933 — — 933 56,979 22,654 — — 79,633 Operating costs and expenses: Cost of clinical laboratory services 33,282 — — — 33,282 Cost of product revenues — 10,411 — — 10,411 Research and development — 1,695 $ 376 — 2,071 Selling, general and administrative 17,967 8,596 — $ 6,578 33,141 Provision for uncollectible accounts receivable 1,910 58 — — 1,968 Legal fee expense 105 70 — 1,079 1,254 Total operating costs and expenses 53,264 20,830 376 7,657 82,127 Operating income (loss) 3,715 1,824 (376 ) (7,657 ) (2,494 ) Other income (expense): Interest (85 ) 34 — 291 240 Other 126 (98 ) — 41 69 Foreign exchange loss — (308 ) — — (308 ) Income (loss) before income taxes $ 3,756 $ 1,452 $ (376 ) $ (7,325 ) $ (2,493 ) Depreciation and amortization included above $ 1,185 $ 1,432 $ — $ 75 $ 2,692 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 74 $ 49 — $ 473 596 Total $ 79 $ 49 $ — $ 473 $ 601 Capital expenditures $ 1,070 $ 354 $ — $ — $ 1,424 Nine months ended April 30, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 52,775 — — — $ 52,775 Product revenues — $ 22,266 — — 22,266 Royalty and license fee income — 1,129 — — 1,129 52,775 23,395 — — 76,170 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 32,009 — — — 32,009 Cost of product revenues — 10,663 — — 10,663 Research and development — 2,002 $ 608 — 2,610 Selling, general and administrative 16,943 8,709 — $ 6,722 32,374 Provision for uncollectible accounts receivable 1,787 (48 ) — — 1,739 Legal fee expense 120 (6 ) — 5,530 5,644 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating costs, expenses and legal settlements, net 52,359 1,370 608 12,252 66,589 Operating income (loss) 416 22,025 (608 ) (12,252 ) 9,581 Other income (expense) Interest (75 ) 38 — (85 ) (122 ) Other 5 35 — 47 87 Foreign exchange loss — (99 ) — — (99 ) Income (loss) before income taxes $ 346 $ 21,999 $ (608 ) $ (12,290 ) $ 9,447 Depreciation and amortization included above $ 1,226 $ 1,568 $ — $ 68 $ 2,862 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 33 $ 19 — $ 313 365 Total $ 38 $ 19 $ — $ 313 $ 370 Capital expenditures $ 1,122 $ 267 $ — $ — $ 1,389

Contingencies

Contingencies	9 Months Ended
	Apr. 30, 2017
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 12 – Contingencies On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. On November 12, 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount was also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company could have been reduced or subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. On February 22, 2016, the Connecticut District Court granted Applera’s motion for summary judgment of non-infringement. The Company appealed that decision. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in part Roche’s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by January 30, 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The parties are waiting for the Courts’ ruling on claim construction. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve an investigation focused primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. During fiscal year 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount is being paid with interest over a five-year period. During fiscal year 2016, the Company accrued an additional $1.5 million, due to the Company’s achievement of certain financial milestones. As of April 30, 2017, the total liability for this settlement is $0.8 million, of which $0.4 million is included in other current liabilities and $0.4 million included in other liabilities. On June 20, 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former attorney’s charging lien for fees allegedly owed for past services rendered to the Company. On December 3, 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the former attorney resolved their respective claims against each other. During the three months ended January 31, 2016, the Company received a total of approximately $7.0 million from the escrow referred to above in accordance with the terms of the Settlement Agreement which was included in the statement of operations under Legal settlements, net within the Life Science segment in that period. On October 9, 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. On January 4, 2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements were included in the statement of operations during the applicable fiscal period under Legal settlements, net within the Life Science segment. On May 16, 2016, the Company reached and finalized a settlement with Life Technologies Corporation in the amount of $24.3 million, net in an infringement action brought by the Company regarding its US Patents No. 6,992,180 and 7,064,197. On July 1, 2016, the Company reached and finalized a settlement with Illumina, Inc., in the amount of $14.5 million, net in an infringement action brought by the Company regarding US Patent No. 7,064,197. These cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements, net within the Life Science segment for the fiscal year ended July 31, 2016. As of April 30, 2017, there are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware alleging patent infringements against various companies. For the cases involving Gen-Probe/Hologic, Roche, and Becton Dickinson, the court has scheduled trial dates in October, November and December 2017, respectively. The court heard summary judgment arguments in those cases on April 4, 2017, but has not ruled on any of the pending summary judgment motions. For the case involving Abbott, the court has set summary judgment briefing deadlines, including a summary judgment hearing in 2017, but has not set a trial date. In the other two cases involving Hologic, one of the cases is stayed pending the resolution of summary judgment motions in the Gen-Probe/Hologic cases, while the other case is proceeding under the court’s scheduling order with fact and expert discovery deadlines through September 2018, a summary judgment hearing date in February 2019, and a trial date in May 2019. There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). We adopted this standard for the fiscal year ending July 31, 2017. The adoption of this update did not have any impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment
Pronouncements Issued but Not Yet Adopted [Policy Text Block]	Pronouncements Issued but Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In May 2017, the FASB issued ASU 2017-09 , “ Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Apr. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: April 30, July 31, Raw materials $ 939 $ 951 Work in process 1,881 1,755 Finished products 4,350 4,265 $ 7,170 $ 6,971

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	9 Months Ended
	Apr. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (1,140 ) (1,140 ) Foreign currency translation (159 ) 121 (38 ) April 30, 2017 $ 27,491 $ (24,247 ) $ 3,244
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite lived, consist of the following: April 30, 2017 July 31, 2016 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (10,931 ) $ 96 $ 11,027 $ (10,905 ) $ 122 Customer relationships 12,034 (8,948 ) 3,086 12,122 (8,331 ) 3,791 Website and acquired content 1,006 (1,006 ) — 1,011 (1,011 ) — Licensed technology and other 481 (450 ) 31 485 (437 ) 48 Trademarks 2,943 (2,912 ) 31 3,005 (2,544 ) 461 Total $ 27,491 $ (24,247 ) $ 3,244 $ 27,650 $ (23,228 ) $ 4,422
Schedule of Useful Lives For Acquisitions [Table Text Block]	At April 30, 2017, information with respect to intangibles assets acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 3.5 years Trademarks 5 years 0.5 year Other intangibles 10 years 2.5 years

Accrued Liabilities and Other23

Accrued Liabilities and Other Current Liabilities (Tables)	9 Months Ended
	Apr. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities consist of the following: April 30, July 31, Payroll, benefits, and commissions $ 3,956 $ 3,956 Professional fees 526 503 Legal fee expense 458 954 Research and development — 300 Other 1,821 2,498 $ 6,761 $ 8,211

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Apr. 30, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	Other liabilities consist of the following: April 30, July 31, Capital lease obligations, net of short term $ 618 $ 794 Accrued legal settlement 400 800 Installment loans, net of short term 39 105 $ 1,057 $ 1,699

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Apr. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Nine months ended 2017 2016 2017 2016 Stock options $ 204 $ 143 $ 586 $ 351 Restricted stock 5 6 15 19 $ 209 $ 149 $ 601 $ 370
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Nine months ended 2017 2016 2017 2016 Cost of clinical laboratory services $ 2 $ 2 $ 5 $ 5 Selling, general and administrative 207 147 596 365 $ 209 $ 149 $ 601 $ 370
Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity during the nine month period ended April 30, 2017: Options Weighted Weighted Aggregate Outstanding at July 31, 2016 1,808,875 $ 3.43 Awarded 493,996 $ 7.07 Exercised (45,358 ) $ 3.28 $ 338 Cancelled or expired (9,000 ) $ 4.74 Outstanding at end of period 2,248,513 $ 4.23 2.7 years $ 10,433 Exercisable at end of period 1,484,993 $ 3.26 1.2 years $ 8,231
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2017 is as follows: Awards Weighted Outstanding at July 31, 2016 8,501 $ 4.13 Awarded — — Vested (2,813 ) $ (3.49 ) Forfeited — — Unvested at end of period 5,688 $ 1.96

Segment reporting (Tables)

Segment reporting (Tables)	9 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 19,584 — — — $ 19,584 Product revenues — $ 7,312 — — 7,312 Royalty and license fee income — 193 — — 193 19,584 7,505 — — 27,089 Operating costs and expenses: Cost of clinical laboratory services 11,334 — — — 11,334 Cost of product revenues — 3,582 — — 3,582 Research and development — 552 $ 214 — 766 Selling, general and administrative 6,118 2,745 — $ 1,639 10,502 Provision for uncollectible accounts receivable 650 (30 ) — — 620 Legal fee expense 4 42 — 466 512 Total operating costs and expenses 18,106 6,891 214 2,105 27,316 Operating income (loss) 1,478 614 (214 ) (2,105 ) (227 ) Other income (expense): Interest (28 ) 12 — 131 115 Other 7 (98 ) — 17 (74 ) Foreign exchange loss — 147 — — 147 Income (loss) before income taxes $ 1,457 $ 675 $ (214 ) $ (1,957 ) $ (39 ) Depreciation and amortization included above $ 390 $ 423 $ — $ 37 $ 850 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 38 $ 23 — $ 146 207 Total $ 40 $ 23 $ — $ 146 $ 209 Capital expenditures $ 483 $ 252 $ — $ — $ 735 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 18,162 — — — $ 18,162 Product revenues — $ 8,001 — — 8,001 Royalty and license fee income — 270 — — 270 18,162 8,271 — — 26,433 Operating costs and expenses: Cost of clinical laboratory services 11,142 — — — 11,142 Cost of product revenues — 3,846 — — 3,846 Research and development — 674 $ 208 — 882 Selling, general and administrative 6,008 2,877 — $ 1,984 10,869 Provision for uncollectible accounts receivable 612 (36 ) — — 576 Legal fee expense 54 11 — 1,567 1,632 Legal settlements, net — — — — — Total operating costs and expenses 17,816 7,372 208 3,551 28,947 Operating income (loss) 346 899 (208 ) (3,551 ) (2,514 ) Other income (expense) Interest (33 ) 7 — (14 ) (40 ) Other 2 4 — 16 22 Foreign exchange loss — 419 — — 419 Income (loss) before income taxes $ 315 $ 1,329 $ (208 ) $ (3,549 ) $ (2,113 ) Depreciation and amortization included above $ 418 $ 514 $ — $ 28 $ 960 Share-based compensation included in above: Cost of clinical laboratory services $ 2 — — — $ 2 Selling, general and administrative 14 $ 9 — $ 124 147 Total $ 16 $ 9 $ — $ 124 $ 149 Capital expenditures $ 331 $ 115 $ — $ — $ 446 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 56,979 — — — $ 56,979 Product revenues — $ 21,721 — — 21,721 Royalty and license fee income — 933 — — 933 56,979 22,654 — — 79,633 Operating costs and expenses: Cost of clinical laboratory services 33,282 — — — 33,282 Cost of product revenues — 10,411 — — 10,411 Research and development — 1,695 $ 376 — 2,071 Selling, general and administrative 17,967 8,596 — $ 6,578 33,141 Provision for uncollectible accounts receivable 1,910 58 — — 1,968 Legal fee expense 105 70 — 1,079 1,254 Total operating costs and expenses 53,264 20,830 376 7,657 82,127 Operating income (loss) 3,715 1,824 (376 ) (7,657 ) (2,494 ) Other income (expense): Interest (85 ) 34 — 291 240 Other 126 (98 ) — 41 69 Foreign exchange loss — (308 ) — — (308 ) Income (loss) before income taxes $ 3,756 $ 1,452 $ (376 ) $ (7,325 ) $ (2,493 ) Depreciation and amortization included above $ 1,185 $ 1,432 $ — $ 75 $ 2,692 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 74 $ 49 — $ 473 596 Total $ 79 $ 49 $ — $ 473 $ 601 Capital expenditures $ 1,070 $ 354 $ — $ — $ 1,424 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 52,775 — — — $ 52,775 Product revenues — $ 22,266 — — 22,266 Royalty and license fee income — 1,129 — — 1,129 52,775 23,395 — — 76,170 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 32,009 — — — 32,009 Cost of product revenues — 10,663 — — 10,663 Research and development — 2,002 $ 608 — 2,610 Selling, general and administrative 16,943 8,709 — $ 6,722 32,374 Provision for uncollectible accounts receivable 1,787 (48 ) — — 1,739 Legal fee expense 120 (6 ) — 5,530 5,644 Legal settlements, net 1,500 (19,950 ) — — (18,450 ) Total operating costs, expenses and legal settlements, net 52,359 1,370 608 12,252 66,589 Operating income (loss) 416 22,025 (608 ) (12,252 ) 9,581 Other income (expense) Interest (75 ) 38 — (85 ) (122 ) Other 5 35 — 47 87 Foreign exchange loss — (99 ) — — (99 ) Income (loss) before income taxes $ 346 $ 21,999 $ (608 ) $ (12,290 ) $ 9,447 Depreciation and amortization included above $ 1,226 $ 1,568 $ — $ 68 $ 2,862 Share-based compensation included in above: Cost of clinical laboratory services $ 5 — — — $ 5 Selling, general and administrative 33 $ 19 — $ 313 365 Total $ 38 $ 19 $ — $ 313 $ 370 Capital expenditures $ 1,122 $ 267 $ — $ — $ 1,389

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
In the Money Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	987,000		865,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		444,000
Weighted Average Stock Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Included In Computation Of Earnings Per Share Amount				337,000
Outstanding Options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	235,000	165,000	282,000

Supplemental disclosure for s28

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$ 1,021	$ 207
Interest Paid	99	112
Installment Loans Financed Amount	69	76
Capital Lease Obligation Cost Basis		1,186
Stock Issued During Period, Value, Employee Benefit Plan	$ 724	$ 709

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Schedule of inventory, current [Abstract]
Raw materials	$ 939	$ 951
Work in process	1,881	1,755
Finished products	4,350	4,265
	$ 7,170	$ 6,971

Goodwill and intangible asset30

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Clinical Labs [Member]
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452

Goodwill and intangible asset31

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
Indefinite-lived Intangible Assets [Line Items]
July 31, 2016	$ 27,650
July 31, 2016	(23,228)
July 31, 2016	4,422
Amortization expense	(1,140)	$ (1,260)
Amortization expense	(1,140)	$ (1,260)
April 30, 2017	27,491
April 30, 2017	(24,247)
April 30, 2017	3,244
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
July 31, 2016	27,650
July 31, 2016	(23,228)
July 31, 2016	4,422
Amortization expense	(1,140)
Amortization expense	(1,140)
Foreign currency translation	(159)
Foreign currency translation	121
Foreign currency translation	(38)
April 30, 2017	27,491
April 30, 2017	(24,247)
April 30, 2017	$ 3,244

Goodwill and intangible asset32

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,491	$ 27,650
Finite-lived intangible assets, Accumulated Amortization	(24,247)	(23,228)
Finite-lived intangible assets, Net	3,244	4,422
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,931)	(10,905)
Finite-lived intangible assets, Net	96	122
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	12,034	12,122
Finite-lived intangible assets, Accumulated Amortization	(8,948)	(8,331)
Finite-lived intangible assets, Net	3,086	3,791
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,006	1,011
Finite-lived intangible assets, Accumulated Amortization	(1,006)	(1,011)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	481	485
Finite-lived intangible assets, Accumulated Amortization	(450)	(437)
Finite-lived intangible assets, Net	31	48
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	2,943	3,005
Finite-lived intangible assets, Accumulated Amortization	(2,912)	(2,544)
Finite-lived intangible assets, Net	$ 31	$ 461

Goodwill and intangible asset33

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	9 Months Ended
	Apr. 30, 2017
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	3 years 6 months
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Weighted average remaining useful life	6 months
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	2 years 6 months
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Loan Payable (Details)

Loan Payable (Details)	9 Months Ended	12 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
Debt Disclosure [Abstract]
Nominal Interest Rate	5.25%	5.25%
Debt Instrument, Interest Rate During Period	14.30%	11.40%
Line of Credit Facility Expiration Month and Year	December 7, 2016

Accrued Liabilities and Other35

Accrued Liabilities and Other Current Liabilities (Details) - Accrued liabilities - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 3,956	$ 3,956
Professional fees	526	503
Legal fee expense	458	954
Research and development		300
Other	1,821	2,498
	$ 6,761	$ 8,211

Other Liabilities (Details)

Other Liabilities (Details) - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Other Liabilities (Details) [Line Items]
Other Liabilities, Current	$ 797	$ 943
Accrued Legal Settlement Current	400
Accrued Legal Settlement	400
Clinical Labs [Member] | Capital Lease Obligation [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Interest Included in Payments	140
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	861
Other Liabilities, Current	243
Clinical Labs [Member] | Installment Loans [Member]
Other Liabilities (Details) [Line Items]
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments	186
Other Liabilities, Current	$ 147

Other Liabilities (Details) - S

Other Liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 1,057	$ 1,699
Capital Lease Obligations [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	618	794
Accrued Legal Settlement [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	400	800
Installment Loans [Member]
Other Liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 39	$ 105

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01		$ 0.01
Maximum Offering Price Under Sales Agreement	$ 20,000,000			$ 20,000,000
Percentage of Commission Payable on Equity Offering	3.00%
Excess Tax Benefit from Share-based Compensation, Financing Activities	$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 1,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	20 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 10,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Remaining Contractual Terms	7 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 19,000	30,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	333,000
Stock Issued During Period, Value, Employee Benefit Plan	$ 724,000	$ 709,000
Stock Issued During Period, Shares, Employee Benefit Plan (in Shares)	91,541	160,352

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 209	$ 149	$ 601	$ 370
Options [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	204	143	586	351
Restricted Stocks [Member]
Stockholders' Equity (Details) - Schedule of share-based compensation expense [Line Items]
Stock Based Compensation Expense	$ 5	$ 6	$ 15	$ 19

Stockholders' Equity (Details40

Stockholders' Equity (Details) - Schedule of share-based compensation expense by line item - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 209	$ 149	$ 601	$ 370
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	2	2	5	5
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Payment Arrangement	$ 207	$ 147	$ 596	$ 365

Stockholders' Equity (Details41

Stockholders' Equity (Details) - Schedule of stock option plans $ / shares in Units, $ in Thousands	9 Months Ended
	Apr. 30, 2017USD ($)$ / sharesshares
Schedule of stock option plans [Abstract]
Outstanding at July 31, 2016 | shares	1,808,875
Outstanding at July 31, 2016 | $ / shares	$ 3.43
Awarded | shares	493,996
Awarded | $ / shares	$ 7.07
Exercised | shares	(45,358)
Exercised | $ / shares	$ 3.28
Exercised | $	$ 338
Cancelled or expired | shares	(9,000)
Cancelled or expired | $ / shares	$ 4.74
Outstanding at end of period | shares	2,248,513
Outstanding at end of period | $ / shares	$ 4.23
Outstanding at end of period	2 years 255 days
Outstanding at end of period | $	$ 10,433
Exercisable at end of period | shares	1,484,993
Exercisable at end of period | $ / shares	$ 3.26
Exercisable at end of period	1 year 73 days
Exercisable at end of period | $	$ 8,231

Stockholders' Equity (Details42

Stockholders' Equity (Details) - Schedule of restricted stock awards	9 Months Ended
	Apr. 30, 2017$ / sharesshares
Schedule of restricted stock awards [Abstract]
Outstanding at July 31, 2016 | shares	8,501
Outstanding at July 31, 2016 | $ / shares	$ 4.13
Vested | shares	(2,813)
Vested | $ / shares	$ (3.49)
Unvested at end of period | shares	5,688
Unvested at end of period | $ / shares	$ 1.96

Income taxes (Details)

Income taxes (Details)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	82.00%	82.00%	4.20%	3.10%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent				34.00%

Segment reporting (Details)

Segment reporting (Details)	9 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Segment Reporting Information [Line Items]
Clinical laboratory services	$ 19,584	$ 18,162	$ 56,979	$ 52,775
Product revenues	7,312	8,001	21,721	22,266
Royalty and license fee income	193	270	933	1,129
Total revenues	27,089	26,433	79,633	76,170
Cost of clinical laboratory services	11,334	11,142	33,282	32,009
Cost of product revenues	3,582	3,846	10,411	10,663
Research and development	766	882	2,071	2,610
Selling, general and administrative	10,502	10,869	33,141	32,374
Provision for uncollectible accounts receivable	620	576	1,968	1,739
Legal fee expense	512	1,632	1,254	5,644
Legal settlements, net				(18,450)
Operating income (loss)	(227)	(2,514)	(2,494)	9,581
Other	(74)	22	69	87
Foreign exchange gain (loss)	147	419	(308)	(99)
Share-based compensation	209	149	601	370
Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	2	2	5	5
Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	207	147	596	365
Clinical Labs [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	19,584	18,162	56,979	52,775
Total revenues	19,584	18,162	56,979	52,775
Cost of clinical laboratory services	11,334	11,142	33,282	32,009
Selling, general and administrative	6,118	6,008	17,967	16,943
Provision for uncollectible accounts receivable	650	612	1,910	1,787
Legal fee expense	4	54	105	120
Legal settlements, net				1,500
Total operating expenses	18,106	17,816	53,264	52,359
Operating income (loss)	1,478	346	3,715	416
Interest	(28)	(33)	(85)	(75)
Other	7	2	126	5
Income (loss) before income taxes	1,457	315	3,756	346
Depreciation and amortization included above	390	418	1,185	1,226
Capital expenditures	483	331	1,070	1,122
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	2	2	5	5
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	38	14	74	33
Clinical Labs [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	40	16	79	38
Life Sciences [Member]
Segment Reporting Information [Line Items]
Product revenues	7,312	8,001	21,721	22,266
Royalty and license fee income	193	270	933	1,129
Total revenues	7,505	8,271	22,654	23,395
Cost of product revenues	3,582	3,846	10,411	10,663
Research and development	552	674	1,695	2,002
Selling, general and administrative	2,745	2,877	8,596	8,709
Provision for uncollectible accounts receivable	(30)	(36)	58	(48)
Legal fee expense	42	11	70	(6)
Legal settlements, net				(19,950)
Total operating expenses	6,891	7,372	20,830	1,370
Operating income (loss)	614	899	1,824	22,025
Interest	12	7	34	38
Other	(98)	4	(98)	35
Foreign exchange gain (loss)	147	419	(308)	(99)
Income (loss) before income taxes	675	1,329	1,452	21,999
Depreciation and amortization included above	423	514	1,432	1,568
Capital expenditures	252	115	354	267
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	23	9	49	19
Life Sciences [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	23	9	49	19
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	214	208	376	608
Total operating expenses	214	208	376	608
Operating income (loss)	(214)	(208)	(376)	(608)
Income (loss) before income taxes	(214)	(208)	(376)	(608)
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	1,639	1,984	6,578	6,722
Legal fee expense	466	1,567	1,079	5,530
Total operating expenses	2,105	3,551	7,657	12,252
Operating income (loss)	(2,105)	(3,551)	(7,657)	(12,252)
Interest	131	(14)	291	(85)
Other	17	16	41	47
Income (loss) before income taxes	(1,957)	(3,549)	(7,325)	(12,290)
Depreciation and amortization included above	37	28	75	68
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	146	124	473	313
Other Segments [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	146	124	473	313
Consolidated [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	19,584	18,162	56,979	52,775
Product revenues	7,312	8,001	21,721	22,266
Royalty and license fee income	193	270	933	1,129
Total revenues	27,089	26,433	79,633	76,170
Cost of clinical laboratory services	11,334	11,142	33,282	32,009
Cost of product revenues	3,582	3,846	10,411	10,663
Research and development	766	882	2,071	2,610
Selling, general and administrative	10,502	10,869	33,141	32,374
Provision for uncollectible accounts receivable	620	576	1,968	1,739
Legal fee expense	512	1,632	1,254	5,644
Legal settlements, net				(18,450)
Total operating expenses	27,316	28,947	82,127	66,589
Operating income (loss)	(227)	(2,514)	(2,494)	9,581
Interest	115	(40)	240	(122)
Other	(74)	22	69	87
Foreign exchange gain (loss)	147	419	(308)	(99)
Income (loss) before income taxes	(39)	(2,113)	(2,493)	9,447
Depreciation and amortization included above	850	960	2,692	2,862
Capital expenditures	735	446	1,424	1,389
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	2	2	5	5
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	207	147	596	365
Consolidated [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	$ 209	$ 149	$ 601	$ 370

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended							9 Months Ended	12 Months Ended
	Jul. 31, 2016USD ($)	May 31, 2016USD ($)	Jan. 31, 2016USD ($)	Oct. 31, 2015USD ($)	Jan. 31, 2014USD ($)	Nov. 30, 2012	Jun. 30, 2004	Apr. 30, 2017USD ($)	Jul. 31, 2016USD ($)	Jul. 31, 2014USD ($)	Jun. 20, 2014USD ($)
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number							6
Number of Licensee Patents								4
Gain Contingency, Patents Found Not Infringed upon, Number						1
Gain Contingencies Prejudgement Interest					$ 12.5
Period Over Which Settlement Amount Has to Be Paid										5 years
Number Of Pending Cases								7
Subpoena [Member]
Contingencies (Details) [Line Items]
Estimated Litigation Settlement Amount										$ 2
Additional Payment of Litigation Settlement Amount									$ 1.5
Total liability for settlement agreement								$ 0.8
Current liability for settlement agreement								0.4
Other liability for settlement agreement								0.4
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit											$ 7
Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements				$ 6.8
Agilent Technologies, Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements			$ 6.1
Life Technologies Corporation [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements		$ 24.3
Illumina Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements	$ 14.5
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount								$ 48.5